Astroglial cells clear extracellular glutamate through the glutamate transporters,
GLT-1 and GLAST, and subsequently convert the incorporated glutamate into glutamine
by the enzyme, glutamine synthetase (GS). Several forms of acute brain injury are
associated with the increased expression of GS and the decreased expression of GLT-1
and/or GLAST, eventually leading to the accumulation of excitotoxic extracellular
glutamate concentrations. Although of clinical interest, the actual trigger of these
injury-related changes of glial glutamate turnover remains unknown. Our present studies
provide evidence that increases in extracellular glutamate, as present in many brain
injuries, are sufficient to modulate the expression of glutamate transporters and
GS. Subjecting cultured cortical astrocytes to glutamate concentrations of 0.5-20
mM resulted in a 25% loss of GLT-1 and GLAST protein levels after 24 h; GLT-1 and
GLAST levels maximally decreased by 40% and 75%, respectively, after 72 h. This decline
was not due to astroglial cell death, since glutamate up to 50 mM did not affect the
survival of cultured astrocytes within 72 h. Major astrocytic cell death, however,
occurred in cultures maintained under severe (4% O(2)), but not mild (9% O(2)), hypoxia,
as well as in the presence of aspartate (>or=20 mM). Glutamate at >or=1 mM induced
a prolonged increase of GS expression in contrast to glutamate transporters. Neither
the decline of glutamate transporter expression nor the increase in GS expression
induced by high extracellular glutamate was further modulated by mild hypoxia. Whereas
the stimulatory influences of glutamate on GS expression were prevented by the non-competitive
NMDA receptor antagonist, MK801, the inhibitory influences on glutamate transporter
expression were neither sensitive to MK801, the non-competitive mGluR5 antagonist,
MTEP, nor the non-competitive AMPA receptor antagonist, GYKI52466, implying that glutamate
controls glial glutamate transport by a glutamate receptor-independent mechanism.